Isentress launched in Japan
This article was originally published in Scrip
Merck & Cohas launched its first-in-class integrase inhibitor for HIV Isentress (raltegravir) in Japan through its local subsidiaryBanyu. The product, which has orphan status, is indicated in combination with other antiretrovirals in adults who have already received treatment, and is reimbursed at ¥1,510.40 ($14.0) per 400mg tablet. The standard dose is one tablet twice a day, which does not have to be taken with food. Isentress was approved in the US last October and in the EU at the beginning of this year.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.